Complex Regional Pain Syndrome - Pipeline Review, H2 2019

Global Markets Direct’s, ‘Complex Regional Pain Syndrome - Pipeline Review, H2 2019’, provides an overview of the Complex Regional Pain Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Complex Regional Pain Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Complex Regional Pain Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Complex Regional Pain Syndrome

- The report reviews pipeline therapeutics for Complex Regional Pain Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Complex Regional Pain Syndrome therapeutics and enlists all their major and minor projects

- The report assesses Complex Regional Pain Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Complex Regional Pain Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Complex Regional Pain Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Complex Regional Pain Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Bexson Biomedical Inc

Biohaven Pharmaceutical Holding Company Ltd

Grunenthal GmbH

Piramal Enterprises Ltd

Takeda Pharmaceutical Co Ltd

Tetra Bio-Pharma Inc

Allergan Plc

Bexson Biomedical Inc

Biohaven Pharmaceutical Holding Company Ltd

Grunenthal GmbH

Piramal Enterprises Ltd

Takeda Pharmaceutical Co Ltd

Tetra Bio-Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Overview

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Companies Involved in Therapeutics Development

Allergan Plc

Bexson Biomedical Inc

Biohaven Pharmaceutical Holding Company Ltd

Grunenthal GmbH

Piramal Enterprises Ltd

Takeda Pharmaceutical Co Ltd

Tetra Bio-Pharma Inc

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Drug Profiles

BHV-5000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydromorphone hydrochloride (intrathecal infusion) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTRX-07 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

soticlestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Product Development Milestones

Featured News & Press Releases

Feb 05, 2019: Tetra Bio-Pharma redefines quality standards for pharmaceutical grade cannabis-derived products

Mar 14, 2018: Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H2 2019

Number of Products under Development ...

List of Tables

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Allergan Plc, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Bexson Biomedical Inc, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Grunenthal GmbH, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Piramal Enterprises Ltd, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Tetra Bio-Pharma Inc, H2 2019

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects, H2 2019

List of Figures

List of Figures

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H2 2019

Number of Products under Development ...

List of Figures

Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports